Life Sciences Funds Suffer Losses Last Month

Casdin Capital led the way downward in August in what was another mixed month for the hedge fund group.


Getty Images

Several biopharma and life sciences hedge funds suffered sharp losses in August after the shares of one of their top holdings tanked following bad news.

It’s business as usual for the volatile group, which is used to huge one day surges or collapses in their investments after a company makes a significant announcement related to a clinical trial or financial results.


To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.